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Introduction
Zidovudine (3′-azido-3′deoxythimidine, azydothymidine, 
AZT, 1-[(2R, 4S, 5S)-4-azido-5-(hydroxymethyl) oxolan-2-
yl]-5-methyl-pyrimidine-2, 4-dione) is a thymidine analog 
that inhibits the replication of the human immunode-
ficiency virus. It was the first approved anti-HIV drug1 
and has been used for the treatment of AIDS, since the 
late 1980s. However, AZT therapy using conventional for-
mulations is frequently associated with dose-dependent 
adverse reactions, mainly anemia and neutropenia2,3.
Zidovudine is known to be rapidly absorbed from the 
gastrointestinal tract, presenting a presystemic biotrans-
formation and an oral bioavailability of ca. 63%4,5. Since 
AZT has a short plasma elimination half life (~1 h)4,5, 
quite large dosages are required to sustain its therapeutic 
level. When orally administered, these cause consider-
able damage at the gastrointestinal level. Furthermore, 
since zidovudine’s antiviral activity is time-dependent, an 
adequate zero-order delivery of AZT is required for pre-
serving anti-HIV action and minimizing the side effects.
ReseaRch aRtIcle
New sustained release of Zidovudine Matrix tablets − 
cytotoxicity toward Caco-2 cells
Jucimary V. Santos1,2, Maria Eugénia T. Pina2, M. Paula M. Marques1,3, and  
Luís A. E. Batista de Carvalho1
1Unidade de I&D “Química-Física Molecular”, Department of Chemistry, Faculty of Science and Technology,  
University of Coimbra, Coimbra, Portugal, 2Centro de Estudos Farmacêuticos (CEF), Pharmaceutical Technology 
Laboratory, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal, and 3Department of Life Sciences,  
Faculty of Science and Technology, University of Coimbra, Portugal 
abstract
Objective: The aim of this study was to adjust the zidovudine (AZT) release from solid tablets to an ideal profile, by 
developing matrices comprising swellable polymers with nonswellable ones.
Methods: Directly compressed matrices comprised different ratios of hydroxypropylmethylcellulose K15M and 
K100M, ethylcellulose, and methacrylic acid (Eudragit® RS PO and Eudragit® RL PO) were prepared. Technological 
characterization and evaluation of the in vitro release behavior were carried out. Cell density and viability following 
drug exposure were evaluated by the SRB method, for the Caco-2 line, while cell morphology was assessed upon 
Trypan blue staining.
Results: A specific formulation containing 5% of each excipient − HPMC K15M, HPMC K100M, Eudragit® RS PO, and 
Eudragit® RL PO − was found to yield the best release profile. Application of the Korsmeyer–Peppas model to the 
dissolution profile evidenced that a non-Fickian (anomalous) transport is involved in the drug release. Regarding 
the influence of the tablets’ composition on the drug’s cytotoxic effect toward the Caco-2 cell line, a reduction of cell 
biomass (0–15%) was verified for the distinct AZT formulations tested, F19 having displayed the highest cytotoxicity, 
after 24 and 48 h of incubation. Additionally, a high reversibility of the AZT effect was observed.
Conclusions: The results showed that the simultaneous application of both hydrophilic and hydrophobic polymers 
can modulate the drug release process, leading to an improved efficacy and patient compliance. All AZT formulations 
studied were found to be cytotoxic against Caco-2 cells, F19 being the most effective one.
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The bioavailability of a particular drug, as well as its 
pharmacokinetics and pharmacodynamics, is strongly 
dependent on the dosage form used. A thorough under-
standing of the phenomena taking place upon exposure 
of a given body to a certain pharmacological agent is thus 
essential for the development of improved controlled 
release drug formulations. Sustained drug delivery sys-
tems are designed to achieve a continuous release of a 
pharmaceutical agent at a predictable and reproduc-
ible kinetics, over an extended period of time, with a 
consequent minimization of drug-related deleterious 
side effects and improved patient compliance, which is 
greater in the case of oral formulations6–9.
Since the newly established protocol ruling toxico-
logical tests10,11 severely limits the use of animals in lethal 
experiments, there has been an increased interest in in 
vitro techniques, for obtaining reliable biological data12,13. 
The human cell line Caco-2, in particular, has shown to 
be a suitable and reliable model for this kind of studies14, 
as it is derived from human colon adenocarcinoma cells 
and exhibits several classes of different markers typically 
found in adult’s intestinal differentiated cells (e.g., alka-
line phosphatase and microvilli in the brush border)15–19. 
In fact, the use of Caco-2 cells in cytotoxicity evaluation 
experiments presents several advantages: (i) there are 
no significant differences in either the morphologi-
cal or physiological characteristics of intestinal cancer 
cells compared to normal cells15,20; (ii) it allows to gather 
information on the potential drug’s toxicity toward the 
mucosa21–23; (iii) it provides information, at the cellular 
level, on drug’s absorption, metabolism, and transport 
through the intestinal wall24–29.
Despite the several studies reported to date on AZT 
sustained release formulations, seeking an optimized 
therapy for HIV/AIDS30–41, no reports have been found 
on their prospective clinical application. However, the 
severity of HIV and its related disorders urges for reliable 
strategies on oral sustained release formulations, par-
ticularly regarding AZT. The present work aims at con-
tributing to this goal, of the utmost relevance for human 
health, by assessing the suitability of several hydrophilic 
and hydrophobic polymer mixtures. A novel approach is 
presented for the promotion of the drug’s gastrointestinal 
absorption, increasing its bioavailability at a therapeuti-
cally adequate rate and leading to a higher therapeutic 
efficiency coupled to a lower toxicity. For those formu-
lations, yielding the best drug release behavior, the anti-
proliferative and cytotoxic properties against Caco-2 cells 
were also evaluated.
Methods
Materials
Drug: Zidovudine (lot. n° 061218) was purchased 
from CIPLA, India. Polymers: Eudragit® RS PO (lot. n° 
0400938137) and Eudragit® RL PO (lot. n° 0410836093) 
Röhm Pharma − Germany; Ethylcellulose 48.9% 
lot. n° 036k0185, Sigma-Aldrich− Germany, USA; 
Hydroxypropylmethylcellulose, Methocel® K15M lot n° 
OG20012N31 and Methocel® K100M lot n° OB12012N11, 
Colorcon − England. Diluent: lactose monohydrate (lot 
n° 10162230), Granulac® 200, Meggle, Wasserburg, 
Germany. Glidant: Talc. Lubricant: magnesium stearate 
(Magnesia GmbH, Germany).
Dulbecco’s modified Eagle’s medium (DMEM), ethyl-
enediamine tetraacetic acid (EDTA), nonessential amino 
acids (NeAA), phosphate buffer saline solution (PBS− 
KH
2
PO
4
-15 mM, NaHPO
4
-43 mM, KCl-27 mM, pH 7.4), 
potassium chloride, potassium phosphate monobasic, 
sodium bicarbonate, sodium chloride, sodium pyruvate, 
sulforhodamine B (SRB), Trypan blue (0.04% (w/v) solu-
tion in PBS), Tris(hydroxymethyl)aminomethane, as well 
as all the reagents and media for cell culturing, were sup-
plied by Sigma-Aldrich (Portugal). Fetal bovine serum 
(FBS) lot n° 41F3676F and trypsin/EDTA were purchased 
from GIBCO (Spain).
The human Caucasian colon adenocarcinoma cell line 
Caco-2 was made available by IPATIMUP (Institute of 
Molecular Pathology and Immunology of the University 
of Porto, Portugal).
Preparation of the matrix tablets
The distinct formulations of the matrix tablets analyzed 
along this study are comprised in Table 1. Both drug and 
excipients were sieved (125 mesh) and thoroughly mixed 
in a plastic bag for 15 min. Talc and magnesium stearate 
were sieved (200 mesh), added to the previous mixture and 
blended for 5 min more. All matrices containing 300 mg 
of zidovudine were directly compacted in an automatic 
hydraulic press (Specac Press, UK), using flat 10 mm diam-
eter punches and a compaction pressure of 100 MPa42.
Raman spectroscopy
The Raman spectra were obtained on a triple monochro-
mator Jobin-Yvon T64000 Raman system (focal distance 
0.640 m, aperture f/7.5) equipped with holographic grat-
ings of 1800 grooves.mm−1. The premonochromator stage 
was used in the subtractive mode. The detection system 
was a liquid nitrogen cooled non-intensified 1024 × 256 
pixel (1”) Charge Coupled Device (CCD) chip. A coher-
ent (model Innova 300-05) Ar+ laser was used as the light 
source, the output of which, at 514.5 nm, was adjusted to 
provide 80 mW at the sample position. A 90° geometry, 
between the incident radiation and the collecting system, 
was employed. The entrance slit was set to 100 μm. Up 
to 10 to 20 scans, with integration times between 12 and 
30 s, were used in all experiments.
Samples were sealed in Kimax glass capillary tubes 
of 0.8 mm inner diameter. Under the above mentioned 
conditions, the error in wavenumbers was estimated to 
be within 1 cm−1.
Weight, diameter, thickness, hardness, and  
friability of the tablets
A total of 20 tablets were checked for weight uniformity 
(KERN 770, electronic balance, Germany), diameter, 
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thickness (Precision micrometer, Roche, Switzerland), 
hardness (TAXT plus texture analyzer, UK), and friability 
(Erweka TA 20, Germany).
In vitro release studies
AZT release from different formulations was measured 
for 12 h, at 37°C ± 2.0°C, by the USP Method 1 (USP31, 
2008) in 900 mL of dissolution media − either simulated 
gastric (pH 1.2) or intestinal (phosphate buffer pH 6.8) 
fluids without enzymes − using a dissolution apparatus 
(Vankel VK-7000 dissolution testing station, Edison, NJ, 
USA) with a stirring speed of 50 rpm.
Sink conditions were kept constant throughout the 
test. The matrices were initially placed in simulated 
gastric fluid. After 2 h, the pH of the medium was varied 
from 1.2 to 6.8 (simulated intestinal fluid). At suitable 
intervals, 5 mL samples were withdrawn and imme-
diately replaced with equal volumes of the respective 
dissolution medium (maintained at 37 ± 2.0°C). The 
samples were filtered (45 µm), diluted, and spectropho-
tometrically analyzed for the AZT content, at λ = 266 nm, 
according to the validation procedure previously 
described43.
The drug release profiles were represented through 
plots of the cumulative percentage of drug release (cal-
culated from the total amount of AZT contained in each 
matrix) versus time. Each independent experiment was 
performed in triplicate.
Kinetic mechanism and release parameters
The tablet’s dissolution profiles can be characterized 
following mathematical model-dependent or model-
independent methods44. According to the extensively 
used model-dependent approach, the release kinetics 
of zidovudine formulations was described by finding the 
best fit of the data (fraction of drug released versus time) 
to distinct mathematical functions: zero-order, first-
order, Higuchi45,46 and Hixson-Crowell47. Furthermore, to 
gain some insight into the drug release mechanism, the 
Korsmeyer–Peppas semi-empirical model was applied48. 
After fitting these models to the dissolution data, their 
performance was based on the determination coefficient 
(r2) comparison.
On the other hand, model-independent methods 
included: the time to release x% of drug from the tablet 
(t
x%
), the sampling time (%
yh
), that is, the percentage of 
drug release after y hours, the mean dissolution times 
(MDT) and the dissolution efficiency (DE).
MDT was calculated in accordance with the following 
Equation (1):
MDT
t Q
Q
j j
j
=
∆
∆
=
=
ˆ
,
j 1
n
j 1
n
∑
∑
 (1)
 where j is the sample number, n the number of time 
increments considered, t jˆ  is the time at midpoint 
between t
j
 and t
j−1
; and ΔQ
j
 is the additional amount of 
drug dissolved in the period of time between t
i
 and t
i−1
.
DE, in turn, is defined for a pharmaceutical dosage 
form49,50 as the area under the dissolution curve for 
a certain period of time expressed as a percentage of 
the area of the rectangle that represents 100% dissolu-
tion at the same time point. It can be calculated by the 
Equation (2), y being the drug percentage dissolved 
at time t.
Table 1. Composition of the distinct AZT formulations containing hydrophilic and hydrophobic polymers.
Formulations
Components (mg)
AZT HPMC K 100M HPMC K 15M EC ERS PO ERL PO Lactose Talc Mg Stearate
F1 300.0 – – 46.0 – – 30.0 2.0 2.0
F2 300.0 – – 38.0 – – 38.0 2.0 2.0
F3 300.0 – – 26.0 – – 50.0 2.0 2.0
F4 300.0 – – 23.0 – – 53.0 2.0 2.0
F5 300.0 – – – 23.0 23.0 30.0 2.0 2.0
F6 300.0 – – – 20.0 26.0 30.0 2.0 2.0
F7 300.0 – – – 38.0 38.0 – 2.0 2.0
F8 300.0 – – – 20.0 56.0 – 2.0 2.0
F9 300.0 23.0 23.0 – – – 30.0 2.0 2.0
F10 300.0 19.0 19.0 – – – 38.0 2.0 2.0
F11 300.0 13.0 13.0 – – – 50.0 2.0 2.0
F12 300.0 11.5 11.5 – – – 53.0 2.0 2.0
F13 300.0 – – 23.0 11.5 11.5 – 2.0 2.0
F14 300.0 – – 26.0 10.0 10.0 30.0 2.0 2.0
F15 300.0 – – 38.0 19.0 19.0 – 2.0 2.0
F16 300.0 – – 56.0 10.0 10.0 – 2.0 2.0
F17 300.0 11.5 11.5 – 11.5 11.5 30.0 2.0 2.0
F18 300.0 13.0 13.0 – 10.0 10.0 30.0 2.0 2.0
F19 300.0 19.0 19.0 – 19.0 19.0 – 2.0 2.0
F20 300.0 13.0 13.0 – 25.0 25.0 – 2.0 2.0
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DE
y dt
y t
=
×
×
×0
t
100
100.
∫ (2)
 Moreover, two model-independent methods were used 
to compare the drug dissolution profiles: the difference 
factor (ƒ
1
) and the similarity factor (ƒ
2
)51–54. The ƒ
1
 fac-
tor measures the percentage error between two curves 
(Equation (3)):
f
R T
R
1
t t
t 1
n
t
t 1
n 100,=
−
×
=
=
∑
∑
 (3)
 where n is the number of dissolution sample times, 
and R
t
 and T
t
 are either the individual or mean per-
centage dissolved of either the reference or test prod-
ucts at each time point t, respectively. This factor is 0, 
when the test and drug reference dissolution profiles 
are identical, and increases proportionally with their 
difference.
The ƒ
2
 factor is a logarithmic reciprocal square root 
transformation of one plus the mean squared differences 
of the drug percentage dissolved between the reference 
and test products (Equation (4)):
f n R T2 t t
1 2
50 log 1 (1 )
2
100 .
t=1
n
= + − ×
−
∑








 (4)
 This similarity factor is 100 when the reference and test 
dissolution profiles are identical and tends to 0 as the dis-
similarity increases. Two dissolution profiles are declared 
similar, if the ƒ
1
 value is lower than 15 (15 to 0) and ƒ
2
 is 
higher than 50 (50 to 100).
In vitro studies on the Caco-2 cell line
Preparation of the drug solutions for in vitro assays
The choice of the drug concentrations to be screened 
in the cell cultures as to their antiproliferative and/or 
cytotoxic effect was based on the drug release profiles 
previously obtained. Therefore, solutions (prepared in 
PBS) were added to the cells sequentially, at 3, 6, 9, 12, 
and 24 h, attaining final concentrations of 92 µM for F9, 
97 µM for F10, and 99 µM for F19.
The solutions were stored at 5°C and protected from 
light. Before administration to the cell cultures, they were 
filtered under sterile conditions (0.22 µm Nylon syringe 
filter with a Luer lock).
Cell culture
The human Caucasian colon adenocarcinoma cell line 
Caco-2 (grown in monolayers) was kept at 37°C ± 0.5°C, 
under 5% CO
2
, in DMEM, supplemented with 10% heat-
inactivated FBS, 1% NeAA, sodium pyruvate and antibi-
otics (100 UI.ml−1 penicillin/100 µg.ml−1 streptomycin). 
Cells were subcultured twice a week, and were harvested 
upon addition of trypsin/EDTA (0.05% trypsin, 0.35 mM 
EDTA.4Na reconstituted in free Ca2+ and Mg2+ balanced 
salt solution).
Cell morphology changes
To assess the drug effect on cell morphology, the cultures 
were observed at the microscope (after staining with 
Trypan blue) upon 48 h of incubation with zidovudine, for 
each formulation tested. The antiviral was then removed, 
the cells were washed with PBS, and their morphological 
aspect was once more examined after an additional 24 h 
of incubation in drug-free medium.
Antiproliferative activity and cytotoxicity evaluation
Cell density and cell viability following drug exposure 
were assessed with the use of standard assays. Cells 
were plated at 1.0 × 105 cells.ml−1 in 24-well dishes and 
incubated overnight (24 h) to allow for cell attachment. 
After seeding, zidovudine (in solution, either pure or in 
a formulation) was added to the medium (at the 3, 6, 9, 
12, and 24 h time points) and the cultures were further 
incubated at 37°C ± 0.5°C for 24 h. For each formula-
tion, as well as for pure AZT, cells were harvested and 
analyzed (both in controls and in drug-treated cultures), 
and the AZT solution was replaced gradually each 3 h, 
to obtain the drug concentration corresponding to the 
release studies, for each experimental condition. Cell 
proliferation and viability were evaluated through the 
SRB staining assay55–59. The optical density of the samples 
was measured at 540 nm, in a microplater reader (Biotek 
µQuant MQX200, Sweden).
Reversibility of the drug effect
Cells were seeded at 1.0 × 105 cells.ml−1, grown to 80% con-
fluence and exposed to zidovudine (for each formulation 
and also for pure AZT) for 24 h. Reversibility of the drug 
effect was then tested by replacing the drug-containing 
medium by fresh culture medium and assessing the cell 
viability following an additional 3 days of incubation. 
Cell density and viability were determined by the SRB 
method.
Statistics
All experiments were carried out in triplicate. The results 
are expressed as mean values ± SD (the corresponding 
error bars being displayed in the graphical plots).
Statistical analyses were performed using analysis of 
variance (ANOVA), followed by post hoc test of Fisher’s 
Protected Least Significant Difference. In view of assess-
ing the statistical significance between the data, a sin-
gle-factor ANOVA was carried out, at a 5% significance 
level. Additionally, the post-test and Bonferroni multiple 
comparison were performed, which related pairs of indi-
vidual samples, checking that the values were statistically 
different. The software SPSS Statistics for Windows (ver-
sion 16.0) was used in this analysis.
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Results and discussion
Preformulation studies
Excipients containing reactive functional groups may 
give rise to chemical and physical transformations. 
Thus, when studying new pharmaceutical formulations, 
it is important to determine the presence of possible 
incompatibilities between their components. Raman 
spectroscopy, which has been widely applied to this type 
of preformulation studies60–63, was presently used with a 
view to detect solid-state interactions between AZT and 
the considered excipients and, consequently, to assess 
the drug-excipients compatibility in all examined for-
mulations. A 1:1 (w:w) drug:excipient ratio was chosen, 
since this is known to maximize the likelihood of observ-
ing intermolecular interactions.
Raman spectra in the 150–3650 cm−1 region are pre-
sented in Figure 1, for both AZT and each of the pure 
polymers used. An analysis of these spectra revealed very 
strong similarities between different forms of hydroxypro-
pylmethylcellulose (HPMC K15M and K100M; Figures 1B 
and C, respectively). The same is observed to Eudragits® 
(RL PO and RS PO; Figure 1E and F, respectively).
Figures 2A and A comprise the Raman spectra of the 
AZT:HPMC K15M and AZT:Eudragit® RS PO physical 
mixtures, respectively. In an attempt to detect changes in 
the drug molecule upon mixing with each polymer, these 
spectra were subtracted from those of the excipients 
(Figures 2B and 3B) to obtain the “AZT changed” spectra 
(Figures 2C and 3C). The similarity between the latter and 
the spectrum of pure AZT (Figure 1A) allows to conclude 
that there are no significant intermolecular interactions 
that could eventually lead to an incompatibility between 
the drug and the different excipients tested (the results for 
the remaining excipients are present as Supplementary 
Data in Figures S1–S4).
Physical characteristics of AZT-containing matrices
The technological characteristics of the mixtures allows 
the preparation of tablets with a uniform weight as indi-
cated by the very low standard deviation in all formula-
tions, well inside the pharmacopoeia limits (R.S.D. < 1%, 
Table S1).
It is well known that tablets’ thickness values may 
vary, depending of the flow characteristics of the pow-
ders. The assessments made in the formulations under 
study show low thickness relative standard deviation (< 
1%), evidencing that the powder filled the punch cavity 
homogeneously due to its good flow behavior.
The matrices’ hardness always remained within 
acceptable limits (96–103 N). However, as this analysis 
is not an absolute indicator of strength, friability was 
also measured: in all formulations, tablets friability was 
less than 1%, within the USP 31 limits. Small values 
imply much less friability during transportation, which 
Figure 1. Raman spectra, in the 150–3650 cm−1 region, of AZT (a), 
HPMC K15M (b), HPMC K100M (c), etilcelulose (d), Eudragit® RL 
PO (e), Eudragit® RS PO (f ), and lactose (g).
Figure 2. Raman spectra, in the 150–3650 cm−1 region, of 
AZT:HPMC K15M physical mixture (a), pure HPMC K15M (b), 
and the result of subtraction (c).
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is important in terms of tablets. Moreover, there was 
accordance between friability and hardness assessments 
(Table S1).
Drug release analysis
Drug release from hydrophilic matrices was found to be 
affected by: (a) water diffusion through the matrix; (b) 
drug diffusion through the hydrated matrix; and (c) ero-
sion of the hydrated matrix. The ratios of AZT released 
from the matrices, for a 12-h period, are depicted in 
Figures 4–8. As can be observed, the ratio for all formu-
lations does not show statistically significant differences 
(p > 0.05) from unity, in any case.
Polymeric matrices containing ethylcellulose alone 
(F1–F4) did not attain the desired release profile. Due to 
total breakdown of the tablet, virtually all the AZT was 
dissolved after 4 h (Figure 4). However the results sug-
gested that ethylcellulose has the ability to modulate 
the dissolution profiles of the other polymers presently 
studied.
The dissolution profiles of the tablets containing both 
Eudragit® RS PO and RL PO, in different binary mixtures 
(F5–F8), evidence a slight dependence on Eudragit® RS 
PO quantity (Figure 5). Formulations F6 and F8, which 
Figure 5. Drug-release profiles for zidovudine formulations 
containing: Eudragit® RS PO and Eudragit® RL PO.
Figure 6. Drug-release profiles for zidovudine formulations 
containing: HPMC K15M and HPMC K100M.
Figure 7. Drug-release profiles for zidovudine formulations 
containing: EC, Eudragit® RS PO and RL PO.
Figure 3. Raman spectra, in the 150–3650 cm−1 region, of AZT: 
Eudragit® RS PO physical mixture (a), pure Eudragit® RS PO (b), 
and the result of subtraction (c).
Figure 4. Drug-release profiles for zidovudine formulations 
containing ethylcellulose.
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have the same amount of Eudragit® RS PO (low perme-
ability) and a roughly 1:2 ratio of Eudragit® RL PO (high 
permeability), show virtually superimposed release 
profiles, evidencing a weak influence of the latter. On 
the other hand, increasing the amount of Eudragit® RS 
PO (F6, F8 < F5 < F7) causes a detectable decrease in the 
quantity of drug released (Figure 5). However, although 
these formulations were shown to be able to prolong the 
release of antiviral (when compared with those contain-
ing only ethylcellulose (F1–F4)), they did not meet the 
criteria required for an extended release, since more than 
80% of the drug was liberated after 4 h.
The use of HPMC, either K100M or K15M, as the sole 
excipient in the matrix was also tested, but the drug was 
not released in a 24-h interval. Thus, matrices contain-
ing both HPMC K15M and HPMC K100M were then 
prepared (F9–F12) and their dissolution profile was 
analyzed (Figure 6). By simple observation, during the 
release tests, it may be concluded that the drug diffusion 
coefficient was dependent on the water quantity in the 
tablets. The diffusion is very slow, since the water may act 
as a plasticizer or form stable bonds (hydrogen bonds) 
between these polymers.
Tablets comprising a high quantity of HPMC (F9 and 
F10) presented a delayed drug release when compared 
with the ones containing a low proportion of polymers 
(Figure 6). This confirms that the drug:polymer ratio is 
an important factor affecting the drug release rates from 
HPMC matrices64-66. The gel layer that is formed delays 
further water uptake and the release of the dissolved 
drug. The percentages of released AZT from the simple 
HPMC mixtures tested were between 76.0% and 84.1%, 
after 12 h.
Although the formulations containing only ethylcel-
lulose (F1–F4) correspond to a drug release higher than 
90% in 4 h, it was decided to associate this polymer with 
the Eudragits (F13–F16), as some studies have reported 
its ability to delay the release process67,68. In fact, the AZT 
release profiles presently obtained seem to be depen-
dent of the EC:Eudragit® proportion: matrices with a 
unit ratio (F13 and F15) displaying very similar release 
profiles (Figure 7), and as the EC/Eudragit® ratio is 
increased (1.3 for F14 and 2.8 for F16), the drug release 
becomes slower. Moreover, the zidovudine release after 
12 h appears to be virtually independent of the ethylcel-
lulose quantity (94.0% to 99.1%).
After testing binary and ternary mixtures, quaternary 
ones were used. Formulations containing both HPMC 
and Eudragit® (F17-F20) gave rise to AZT dissolution 
values between 90.5% and 98.1% after 12 h (Figure 8). 
In general, the process of tablet swelling was very rapid, 
leading to a fast release of the drug (higher in gastric than 
in intestinal medium). A significant increase in the zido-
vudine release rate was observed for decreased HPMC 
proportions. The best profile appear to correspond to the 
F19 formulation: it promotes a slightly faster initial drug 
release coupled to a slower transfer, while allowing the 
use of over 90% of the drug.
The change in the dissolution medium (from gastric 
to intestinal) 2 h after adding the initial one, allowed to 
conclude that different pH conditions do not generate 
discontinuities in the drug release profile.
It is generally assumed that water soluble drugs are 
released primarily by diffusion through the “gel layer” 
and that scarcely water soluble drugs are released mainly 
through erosion of this layer. Actually, the release mech-
anism is dictated by the solubility of the drug and both 
mechanisms contribute to the release. It is the relative 
input from each process that is controlled by the drug’s 
solubility69.
The analysis of the drug release behavior for the vari-
ous combinations studied allows verifying that the F9, 
F10, and F19 mixtures can provide kinetics suitable for 
extended release formulations, according to the objec-
tives set.
Kinetic mechanism and release parameters
Dissolution tests at different dissolution pH values 
should be considered, in a preformulation study, in view 
of assessing the good functionality of the therapeutic 
system. Drug release is controlled by different mecha-
nisms with diverging kinetics. Using a gelling agent of 
low viscosity grade (HPMC K15M), erosion of the swol-
len polymer describes the release mechanism70. In turn, 
if high viscosity polymers are applied (HPMC K100M), a 
stable gel is formed and polymer erosion is negligible. In 
addition, the use of water insoluble polymers as tablet 
excipients partly contributed to the prevention of matrix 
disintegration.
Usually, both erosion and diffusion contribute to the 
release of an incorporated drug. The transition between 
the two mechanisms results in a kinetic process generally 
described as “anomalous transport,” considered when 
there is the contribution of both diffusion and relaxation 
processes70–72. The analysis of present experimental data 
in the light of the Korsmeyer–Peppas formalism, as 
well as the interpretation of the corresponding release 
exponent values (n), leads to a better understanding of 
the balance between these mechanisms. Moreover, the 
Figure 8. Drug-release profiles for zidovudine formulations 
containing: HPMC K15M:K100M and Eudragit® RS:RL PO.
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kinetics of AZT release was also determined by finding 
the best fit of the dissolution data (fraction of drug release 
versus time) to distinct models: zero-order, first-order, 
Higuchi, and Hixson-Crowell. This kind of analysis was 
performed for F9, F10, and F19 selected formulations: 
the AZT release profiles (between 10% and 70%) were 
fitted and the results are summarized in Table 2.
The obtained values for the Korsmeyer–Peppas dif-
fusion exponent n (0.57–0.65) suggest that zidovudine 
release from F9, F10, and F19 matrices is controlled by 
both drug diffusion in the hydrated matrix and erosion of 
the matrix. As a result, good fits to both Higuchi (Fickian 
diffusion) and Hixson-Crowell models were achieved 
(the latter being mainly related with changes in the sur-
face area and diameter of the tablets).
Following the well-known Flick’s law, zidovudine dif-
fuses through the stable gel layer according to a square 
root time dependence. In the swelling tablet surface, the 
water molecules diffuse with more difficulty from these 
matrices, since at the beginning of the dissolution stud-
ies, a gel barrier is formed. On the other hand, the time 
for the polymer to relax also decreases and the relaxation 
mechanism becomes more pronounced. The mecha-
nisms of drug release from a polymeric matrix occur in 
the early stage by polymer swelling and the tablet thick-
ness increases. The results indicated that the mecha-
nism of drug release was diffusion coupled with erosion 
(anomalous transport).
The release parameters obtained for the selected for-
mulations are listed in Table 3. Although the MDT values 
are quite similar, those for F9, F10, and F19 formulations 
are slightly higher than the ones obtained for the remain-
ing formulations (Table S2). In fact, the percentage of 
HPMC polymer in the tablets may modify the matrix 
swelling and the release rates. In addition, it is proposed 
that the rate and the drug release mechanism from HPMC 
matrices is almost independent of the ionic strength of the 
medium (pH = 1.2 and pH = 6.8). A significant decrease in 
drug release can be achieved by using a higher amount of 
HPMC K15M:HPMC K100M (F9 %
12h
 = 77).
To compare the MDT profiles obtained, the differences 
between the parameter estimates from each fit are calcu-
lated and a joint confidence region around the vector of 
mean differences is established using the Bonferroni test. 
The F-test indicated that the general level of the profiles 
is similar for both batches. Concerning the other F-test, 
Bonferroni test evidenced that the assumptions about 
the variance matrix of the F9 and F10 were similar. This 
means that, according to this test, the general shape of 
the batches’ profiles is different when a level of signifi-
cance of 5% is considered.
The influence of polymeric matrices on the rate and 
extent of zidovudine release was evaluated (Table 3). 
A significant improvement on the release and exten-
sion rate of the formulations was observed, with a DE
2h
 
of 14.76% to 22.55%. The analysis of variance of the DE 
values shows that the formulation release profiles under 
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The similarity factor (ƒ
2
) has been adopted by US Food 
and Drug Administration52 and European Medicines 
Agency73,74 as a criterion for assessment of similarity 
between two in vitro release profiles. Therefore, in the 
present study, ƒ
2
 was employed to evaluate the release 
profiles of various formulations.
This type of factor analyses are based on a comparison 
between the obtained results and the release profile con-
sidered as ideal. For the type of matrices used, containing 
either hydrophilic or hydrophobic polymers, two optimal 
profiles were considered: (i) an ideal Higuchi profile for 
a total release of the drug in 12 h (K
H
 = 100/12½) and (ii) 
an ideal target profile based on data from the literature 
(release after 2 h: 35%; after 4 h: 52%; after 8 h: 75%) 
according to Table 475,76.
The ƒ
1
 (difference factor) is proportional to the average 
difference between two profiles, whereas ƒ
2
 is inversely 
proportional to the average squared difference between 
the two profiles, with emphasis on the larger difference 
among all time points. In fact, ƒ
2
 is a logarithmic transfor-
mation of the sum-squared error of differences between 
the testing drug release T
t
 and the ideal release R
t
 over all 
time points (n). When ƒ
2
 was > 50, the mean deviation 
over all time points was less than 10%, and the testing 
profile was believed to be similar to the ideal profile. As 
ƒ
1
 and ƒ
2
 are strongly dependent on the last considered 
release point (> 85%), only the release values between 0% 
and 85%51–54 were accounted for in the analysis (Table 5).
The F9 ƒ
1
 and ƒ
2
 values clearly indicate that this for-
mulation does not conform to the desired release pro-
file (Table 5, Figure 9). In turn, formulations F10 and 
F19 showed a clear similarity regarding both the Higuchi 
profile and the ideal target profile established in the 
present work. In particular, F19 which contains a mix-
ture of HPMC and Eudragits® with identical masses 
and without the use of lactose as a diluent, displays a 
strong resemblance with the ideal target profile (Figure 9), 
thus presenting ƒ
1
 and ƒ
2
 values (2.7 and 82.5, respec-
tively) well within the FDA and EMEA criteria (ƒ
1
 ≤ 15 
and ƒ
2
 ≥ 50)52,73,74.
Cell morphology assessment and evaluation of cell 
growth inhibition and cytotoxicity
The evaluation of the effect of the AZT formulations pres-
ently investigated at a cellular level was initially based 
on a microscopic observation of the Caco-2 cultures, to 
understand the morphology and typical organization of 
this cell line, both in the absence and in the presence of 
the drug. Since these cells have a clear tendency to form 
colonies, they were plated at an appropriate density to 
allow this type of distribution. In the drug-free cultures, 
the isolated cells were found to migrate and start to form 
small colonies, which steadily increased in size. In the 
presence of each AZT formulation, in turn, morphologi-
cal changes were observed, namely disruption of the cel-
lular layer and finally cell lysis.
Furthermore, growth-inhibition and cytotoxicity 
evaluation tests were carried out for each of the AZT 
solid matrices studied, as well as for the pure drug (for 
Table 3. Release parameters for selected zidovudine 
formulations.
Parameters
Formulations
F9 F10 F19
t
25%
 (h) 2.18 ± 0.87 1.24 ± 0.95 1.05 ± 0.99
t
50%
 (h) 5.90 ± 1.12 4.01 ± 0.99 3.66 ± 1.03
%
12h
a 76.92 ± 0.99 84.12 ± 1.18 90.50 ± 1.09
MDTa (h) 4.53 ± 0.02 3.84 ± 0.03 3.85 ± 0.04
DE
2h
a (%) 14.76 ± 1.17 20.63 ± 0.96 22.55 ± 1.13
DE
12h
a (%) 48.07 ± 1.23 57.61 ± 0.99 61.46 ± 0.99
a Mean ± S.D. (six measurements).
Table 4. Zidovudine ideal release profiles for a 12-h release 
period (see text).
Time (hours) Ideal target (%) Higuchi (%)
0  0   0
1 20  29
2 35  41
3 44  50
4 52  58
5 59  65
6 65  71
7 70  76
8 75  82
9 80  87
10 84  91
11 88  96
12 92 100
Figure 9. Drug-release profiles for some zidovudine formulations 
compared with both ideal release profiles (see text).
Table 5. Difference (f
1
) and similarity (f
2
) factors for a 0–85% of 
AZT release from selected formulations, relative to both Higuchi 
and target ideal release profiles.
Factors 
Formulations
F9 F10 F19
Higuchi Target Higuchi Target Higuchi Target
f
1
28.0 20.0 12.7 4.4 7.5 2.7
f
2
36.9 45.8 53.2 74.4 64.6 82.5
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comparison purposes). It was verified that exposure of 
the Caco-2 cells to the distinct formulations F9, F10, 
and F19, and to AZT alone, led to a marked viability 
decrease (up to 85%) according to a time-dependent pro-
file (Figure 10). Also, the matrix formulations displayed 
a lower cytotoxic effect as compared to the pure drug 
(no significant statistical difference having been found 
between these results).
Reversibility of the cytotoxic effect
The reversibility of the cytotoxic effect of zidovudine and 
its formulations F9, F10, and F19 against the Caco-2 cell 
line was assessed, by the ability of these cells to resume 
their normal growth process after incubation with the 
drug.
Upon incubation of the cells with the tested formula-
tions for a 48-h period, the drug-containing medium was 
replaced by fresh, drug-free medium. The morphologi-
cal aspect of the culture and the cell viability were then 
assessed, at different time points (3, 6, 9, 12, and 24 h), 
to evaluate the reversibility of the drug effect (Figure 11). 
This was found to be lower for formulation F19 (namely 
after 9, 12, and 24 h upon drug removal). Pure AZT dis-
plays only a slightly lower reversibility relative to these 
formulations − ca. 10% for AZT versus 15% for F19.
The results presently reported evidence of quite a high 
reversibility of the effect exerted by these AZT formula-
tions against the Caco-2 cell line, according to the order: 
F9 > F10 > F19. The maximum loss of cell viability mea-
sured, that is, the maximum percentage of cells that did 
not show the ability to reverse the cytotoxic effect of the 
drug, was found to be 17%, for formulation F19. In fact, 
while for preparations F9 and F10 this effect was com-
pletely reversed after 8 to 10 days of drug removal, for F19 
recovery of normal cell growth was only verified after 
21 days in the absence of zidovudine (Figure 12).
conclusion
Although hydrophilic swellable polymers (e.g., HPMC) 
are widely used to control the release of drugs from 
solid matrix formulations, they do not comply with the 
required AZT release profile when used alone. Therefore, 
it is presently suggested to combine swellable polymers 
with nonswellable ones, aiming at a modulation of 
the liberation process according to the desired release 
profile.
The hydrophobic polymer Eudragit® was tested, since 
it was verified that it was suitable as a matrix agent and 
allowed a direct compression preparation, which is both 
Figure 11. Reversibility of the cytotoxic effect of pure zidovudine 
and the zidovudine formulations F9, F10, and F19 toward the 
Caco-2 cell line, for a drug concentration of 100 µM, 92 µM, 97 
µM, and 99 µM, respectively. Cells were washed and fed with 
fresh media, 48 h following addition of the drug. Cell viability 
was evaluated by the SRB colorimetric assay (as described in 
the “Materials and methods”). (The results represent the mean 
± SD of three independent experiments, performed in triplicate; 
p = 0.02 and F = 3.03, with F
critical
 = 2.54.)
Figure 12. Graphical representation of the reversibility of the 
cytotoxic effect exerted by pure zidovudine and the zidovudine 
formulations F9, F10, and F19 toward the Caco-2 cell line, 
for a drug concentration of 100 µM, 92 µM, 97 µM, and 99 µM, 
respectively. Cell viability was evaluated by the SRB colorimetric 
assay (as described in the Materials and Methods). The dashed 
line represents the removal of the drug.
Figure 10. Time dependence of the cytotoxic effect of pure 
zidovudine and the zidovudine formulations F9, F10, and F19 
toward the Caco-2 cell line, for a drug concentration of 100 µM, 92 
µM, 97 µM, and 99 µM, respectively. Cell viability was evaluated 
by the SRB colorimetric assay (as described in the “Materials 
and methods”). (The results are expressed as a percentage 
of the control (100%), and represent the mean ± SD for three 
independent experiments performed in triplicate; p = 0.53, 
F = 0.80, with F
critical
 = 2.49.)
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simple and economical for industrial uses. All examined 
formulations yielded tablets with good and reproducible 
technological properties. The evaluation of the release 
mechanisms evidenced a non-Fickian (anomalous) 
transport for all tested formulations. Formulation F19, 
containing 5% of each excipient − HPMC K15M, HPMC 
K100M, Eudragit® RS PO, and Eudragit® RL PO − was 
found to be the one yielding the best release profile, that 
is, displaying a higher similarity ƒ
2
 factor relative to the 
two ideal target profiles considered. Moreover, this for-
mulation is lactose-free, which is particularly important 
since most of the patients, especially HIV ones, may 
develop lactose intolerance.
The changes presently observed in the human can-
cer cell line Caco-2 upon administration of zidovudine, 
either alone or in polymeric formulations, were deter-
mined, regarding cell growth and viability as well as cell 
morphology. Overall, the presence of the polymers was 
found to decrease the drug toxicity toward these cancer 
cells, as compared to pure AZT. Formulation F19 was 
found to be the most effective toward these cells, causing 
a viability loss of ca. 15%, 24 h after drug administration. 
Furthermore, the cytotoxicity screening presently carried 
out revealed a quite high reversibility of this effect, F19 
yielding the less reversible viability loss − 21 days to com-
plete recovery in the absence of drug.
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